Publicaciones en colaboración con investigadores/as de Hospital Nacional de Parapléjicos (2)

2024

  1. Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury

    Spinal Cord, Vol. 62, Núm. 8, pp. 454-467

2021

  1. The Selective Loss of Purkinje Cells Induces Specific Peripheral Immune Alterations

    Frontiers in Cellular Neuroscience, Vol. 15